Johnson & Johnson $JNJ is looking to buy eye disease biotech Ollin Biosciences for up to $3.4B, according to the Financial Times.
Ollin raised a $330M Series B in June to fund Phase 3 trials of OLN324, a VEGF/Ang2 bispecific for diabetic macular edema and wet AMD.